Immunome (NASDAQ:IMNM) Coverage Initiated at JPMorgan Chase & Co.

Research analysts at JPMorgan Chase & Co. started coverage on shares of Immunome (NASDAQ:IMNM) in a report released on Tuesday, MarketBeat reports. The firm set an “overweight” rating and a $24.00 price target on the stock. JPMorgan Chase & Co.‘s target price suggests a potential upside of 63.38% from the company’s current price.

IMNM has been the topic of a number of other reports. SVB Leerink started coverage on Immunome in a research report on Monday, January 29th. They set an “outperform” rating and a $30.00 target price on the stock. Wedbush increased their price target on Immunome from $27.00 to $33.00 and gave the company an “outperform” rating in a research report on Monday, April 1st. Leerink Partnrs reissued an “outperform” rating on shares of Immunome in a research report on Monday, January 29th. Finally, Guggenheim started coverage on Immunome in a research report on Monday, April 15th. They issued a “buy” rating and a $35.00 price target for the company. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $30.50.

Immunome Stock Performance

Shares of IMNM opened at $14.69 on Tuesday. Immunome has a 52-week low of $4.50 and a 52-week high of $30.96. The business’s 50 day moving average price is $21.58 and its two-hundred day moving average price is $15.28. The firm has a market cap of $880.52 million, a PE ratio of -2.73 and a beta of 1.66.

Immunome (NASDAQ:IMNM) last issued its quarterly earnings results on Thursday, March 28th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.26). Immunome had a negative net margin of 761.92% and a negative return on equity of 69.74%. The business had revenue of $3.83 million during the quarter, compared to analyst estimates of $3.40 million. Research analysts predict that Immunome will post -1.91 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Dorsey Wright & Associates bought a new position in Immunome in the 3rd quarter valued at $26,000. Jump Financial LLC bought a new position in shares of Immunome during the 4th quarter worth $172,000. Acadian Asset Management LLC bought a new position in shares of Immunome during the 3rd quarter worth $414,000. Clear Creek Financial Management LLC bought a new position in shares of Immunome during the 1st quarter worth $547,000. Finally, Emfo LLC bought a new position in shares of Immunome during the 4th quarter worth $633,000. Institutional investors own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.